CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 133 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $973,000 | +21.3% | 259,439 | +71.8% | 0.03% | +42.1% |
| Q3 2019 | $802,000 | +18.6% | 151,030 | -14.2% | 0.02% | +26.7% |
| Q2 2019 | $676,000 | -49.6% | 175,953 | -50.3% | 0.02% | -46.4% |
| Q3 2018 | $1,340,000 | -37.6% | 353,962 | -48.7% | 0.03% | -31.7% |
| Q2 2018 | $2,148,000 | +38.0% | 690,400 | +6.0% | 0.04% | +24.2% |
| Q1 2018 | $1,557,000 | +123.7% | 651,599 | +271.4% | 0.03% | +120.0% |
| Q4 2017 | $696,000 | +102.3% | 175,467 | +26.8% | 0.02% | +114.3% |
| Q3 2017 | $344,000 | +44.5% | 138,329 | +60.5% | 0.01% | +40.0% |
| Q2 2017 | $238,000 | +107.0% | 86,168 | +46.2% | 0.01% | +66.7% |
| Q1 2017 | $115,000 | +342.3% | 58,940 | +138.1% | 0.00% | +200.0% |
| Q4 2016 | $26,000 | -79.7% | 24,759 | -86.3% | 0.00% | -75.0% |
| Q2 2016 | $128,000 | -37.3% | 180,721 | +3.5% | 0.00% | -33.3% |
| Q1 2016 | $204,000 | – | 174,581 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |